• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Up-dosing of reslizumab in severe asthmatics with persistent sputum eosinophilia: A feasibility study.

作者信息

Mukherjee Manali, Bernaola Jaime, Nolasco Santi, Kjarsgaard Melanie, Xie Yinglan, Radford Katherine, Alotaibi Bashayr, Garrido Carmen Venegas, Nair Parameswaran

机构信息

Department of Medicine, McMaster University, Hamilton, Ontario, Canada.

Research Institute of St. Joe's. St Joseph's Healthcare, Hamilton, Ontario, Canada.

出版信息

Allergy. 2025 Feb;80(2):605-608. doi: 10.1111/all.16322. Epub 2024 Sep 17.

DOI:10.1111/all.16322
PMID:39286951
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11804305/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1bc1/11804305/2fb06d500db5/ALL-80-605-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1bc1/11804305/2fb06d500db5/ALL-80-605-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1bc1/11804305/2fb06d500db5/ALL-80-605-g001.jpg

相似文献

1
Up-dosing of reslizumab in severe asthmatics with persistent sputum eosinophilia: A feasibility study.在持续痰液嗜酸性粒细胞增多的重度哮喘患者中增加瑞利珠单抗剂量：一项可行性研究。
Allergy. 2025 Feb;80(2):605-608. doi: 10.1111/all.16322. Epub 2024 Sep 17.
2
Weight-adjusted Intravenous Reslizumab in Severe Asthma with Inadequate Response to Fixed-Dose Subcutaneous Mepolizumab.体重调整的静脉注射瑞利珠单抗治疗对固定剂量皮下美泊利珠单抗应答不足的重症哮喘。
Am J Respir Crit Care Med. 2018 Jan 1;197(1):38-46. doi: 10.1164/rccm.201707-1323OC.
3
Role of local eosinophilopoietic processes in the development of airway eosinophilia in prednisone-dependent severe asthma.局部嗜酸性粒细胞生成过程在泼尼松依赖型重度哮喘气道嗜酸性粒细胞增多症发生中的作用
Clin Exp Allergy. 2016 Jun;46(6):793-802. doi: 10.1111/cea.12695.
4
Reslizumab and Eosinophilic Asthma: One Step Closer to Precision Medicine?瑞利珠单抗与嗜酸性粒细胞性哮喘：离精准医学更近一步了吗？
Front Immunol. 2017 Mar 10;8:242. doi: 10.3389/fimmu.2017.00242. eCollection 2017.
5
Impaired perception of dyspnea in patients with severe asthma. Relation to sputum eosinophils.重度哮喘患者呼吸困难感知受损。与痰液嗜酸性粒细胞的关系。
Am J Respir Crit Care Med. 1998 Oct;158(4):1134-41. doi: 10.1164/ajrccm.158.4.9710087.
6
Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study.瑞利珠单抗治疗控制不佳的嗜酸性粒细胞性哮喘：一项随机、安慰剂对照研究。
Am J Respir Crit Care Med. 2011 Nov 15;184(10):1125-32. doi: 10.1164/rccm.201103-0396OC. Epub 2011 Aug 18.
7
Effects of Anti-T2 Biologic Treatment on Lung Ventilation Evaluated by MRI in Adults With Prednisone-Dependent Asthma.抗T2生物制剂治疗对依赖泼尼松的成年哮喘患者肺部通气的MRI评估作用
Chest. 2020 Oct;158(4):1350-1360. doi: 10.1016/j.chest.2020.04.056. Epub 2020 May 16.
8
Increased numbers of activated group 2 innate lymphoid cells in the airways of patients with severe asthma and persistent airway eosinophilia.在严重哮喘和持续性气道嗜酸性粒细胞增多症患者的气道中，活化的 2 型固有淋巴细胞数量增加。
J Allergy Clin Immunol. 2016 Jan;137(1):75-86.e8. doi: 10.1016/j.jaci.2015.05.037. Epub 2015 Jul 17.
9
Upper and lower airway inflammation in severe asthmatics: a guide for a precision biologic treatment.严重哮喘患者的上下气道炎症：精准生物治疗的指导。
Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620965151. doi: 10.1177/1753466620965151.
10
Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma.抗白细胞介素-5治疗在难治性嗜酸性粒细胞性哮喘管理中的疗效和安全性证据。
Ther Adv Respir Dis. 2015 Aug;9(4):135-45. doi: 10.1177/1753465815581279. Epub 2015 Apr 21.

引用本文的文献

1
Achieving remission in severe asthma.实现重度哮喘的缓解
Chin Med J Pulm Crit Care Med. 2025 Jun 13;3(2):77-87. doi: 10.1016/j.pccm.2025.05.001. eCollection 2025 Jun.

本文引用的文献

1
Benralizumab Normalizes Sputum Eosinophilia in Severe Asthma Uncontrolled by Anti-IL-5 Antibodies: A Single-Blind, Placebo-controlled Clinical Trial.贝那利珠单抗可使抗IL-5抗体治疗无法控制的重度哮喘患者痰液嗜酸性粒细胞水平恢复正常：一项单盲、安慰剂对照临床试验。
Am J Respir Crit Care Med. 2023 Dec 15;208(12):1330-1335. doi: 10.1164/rccm.202308-1413LE.
2
Suboptimal treatment response to anti-IL-5 monoclonal antibodies in severe eosinophilic asthmatics with airway autoimmune phenomena.在伴有气道自身免疫现象的重度嗜酸性粒细胞性哮喘患者中，对抗白细胞介素-5单克隆抗体治疗反应欠佳。
Eur Respir J. 2020 Oct 8;56(4). doi: 10.1183/13993003.00117-2020. Print 2020 Oct.
3
Weight-adjusted Intravenous Reslizumab in Severe Asthma with Inadequate Response to Fixed-Dose Subcutaneous Mepolizumab.
体重调整的静脉注射瑞利珠单抗治疗对固定剂量皮下美泊利珠单抗应答不足的重症哮喘。
Am J Respir Crit Care Med. 2018 Jan 1;197(1):38-46. doi: 10.1164/rccm.201707-1323OC.
4
Role of local eosinophilopoietic processes in the development of airway eosinophilia in prednisone-dependent severe asthma.局部嗜酸性粒细胞生成过程在泼尼松依赖型重度哮喘气道嗜酸性粒细胞增多症发生中的作用
Clin Exp Allergy. 2016 Jun;46(6):793-802. doi: 10.1111/cea.12695.
5
Mepolizumab treatment in patients with severe eosinophilic asthma.美泊利珠单抗治疗严重嗜酸性粒细胞性哮喘患者。
N Engl J Med. 2014 Sep 25;371(13):1198-207. doi: 10.1056/NEJMoa1403290. Epub 2014 Sep 8.
6
Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial.美泊利单抗治疗严重嗜酸性粒细胞性哮喘（DREAM）：一项多中心、双盲、安慰剂对照试验。
Lancet. 2012 Aug 18;380(9842):651-9. doi: 10.1016/S0140-6736(12)60988-X.